Orthocell (ASX:OCC) Capital Expenditure : A$-0.48 Mil (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Orthocell Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Orthocell's cash flow for capital expenditures for the six months ended in Dec. 2023 was A$-0.42 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.48 Mil.

Orthocell Capital Expenditure Historical Data

The historical data trend for Orthocell's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orthocell Capital Expenditure Chart

Orthocell Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Capital Expenditure

Get a 7-Day Free Trial

-0.37

-0.06

-0.19

-0.54

-0.63

Orthocell Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Capital Expenditure	Get a 7-Day Free Trial															-0.15	-0.39	-0.57	-0.06	-0.42

Orthocell Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.48 Mil.

Orthocell (ASX:OCC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orthocell Ltd (ASX:OCC) » Definitions » Capital Expenditure

Comparable Companies

Traded in Other Exchanges

N/A

Address

90 South Street, Building 191, Murdoch University, Murdoch, Perth, WA, AUS, 6150

Website

https://www.orthocell.com.au

Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialisation of cell therapies and related technologies. Its product includes CelGro is a naturally derived collagen medical device for tissue repair and Ortho-ATI is a first-in-class cell therapy for the treatment of chronic tendon injuries.